Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - estradiol hemihydrate 1.56mg equivalent to 100 µg per 24 hours - transdermal patch - 100 mcg/24h - active: estradiol hemihydrate 1.56mg equivalent to 100 µg per 24 hours excipient: acrylic adhesive dipropylene glycol oleyl alcohol povidone silicone adhesive - the estradot regimen is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis (see dosage and administration and warnings and precautions).

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - estradiol hemihydrate 0.39mg equivalent to oestradiol 25 µg/24hour - transdermal patch - 25 mcg/24h - active: estradiol hemihydrate 0.39mg equivalent to oestradiol 25 µg/24hour excipient: acrylic adhesive dipropylene glycol oleyl alcohol povidone silicone adhesive - the estradot regimen is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis. in women with an intact uterus, oestrogens should always be supplemented by administration of a progestogen.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - estradiol hemihydrate 0.585mg equivalent 37.5 µg/24 hours - transdermal patch - 37.5 mcg/24h - active: estradiol hemihydrate 0.585mg equivalent 37.5 µg/24 hours excipient: acrylic adhesive dipropylene glycol oleyl alcohol povidone silicone adhesive - the estradot regimen is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - estradiol hemihydrate 0.78mg equivalent to 50 µg/24 hours - transdermal patch - 50 mcg/24h - active: estradiol hemihydrate 0.78mg equivalent to 50 µg/24 hours excipient: acrylic adhesive dipropylene glycol oleyl alcohol povidone silicone adhesive - the estradot regimen is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis (see dosage and administration and warnings and precautions).

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - estradiol hemihydrate 1.17mg equivalent to 75 µg per 24 hours - transdermal patch - 75 mcg/24h - active: estradiol hemihydrate 1.17mg equivalent to 75 µg per 24 hours excipient: acrylic adhesive dipropylene glycol oleyl alcohol povidone silicone adhesive - the estradot regimen is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis (see dosage and administration and warnings and precautions).

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - somatropin 6.67 mg/ml - solution for injection - 10 mg/1.5ml - active: somatropin 6.67 mg/ml excipient: dibasic sodium phosphate glycine monobasic sodium phosphate phenol phosphoric acid poloxamer 188 sodium hydroxide water for injection - adults replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in two different dynamic tests for growth hormone deficiency. patients must also fulfill the following criteria. childhood onset: patients, who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. prader-willi syndrome, for improvement of body composition.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - somatropin 10 mg/ml - solution for injection - 15 mg/1.5ml - active: somatropin 10 mg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate phenol phosphoric acid poloxamer 188 sodium chloride sodium hydroxide water for injection - adults replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in two different dynamic tests for growth hormone deficiency. patients must also fulfill the following criteria. childhood onset: patients, who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. prader-willi syndrome, for improvement of body composition.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - somatropin 3.33 mg/ml - solution for injection - 5 mg/1.5ml - active: somatropin 3.33 mg/ml excipient: benzyl alcohol dibasic sodium phosphate mannitol monobasic sodium phosphate phosphoric acid poloxamer 188 sodium hydroxide water for injection - adults replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in two different dynamic tests for growth hormone deficiency. patients must also fulfill the following criteria. childhood onset: patients, who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. prader-willi syndrome, for improvement of body composition.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 0.511mg equivalent to 0.5 mg tacrolimus - capsule - 0.5 mg - active: tacrolimus monohydrate 0.511mg equivalent to 0.5 mg tacrolimus excipient: capsugel ivory g4ics000511 croscarmellose sodium hypromellose lactose monohydrate magnesium stearate - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidneys) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 1.022mg equivalent to 1 mg tacrolimus - capsule - 1 mg - active: tacrolimus monohydrate 1.022mg equivalent to 1 mg tacrolimus excipient: croscarmellose sodium hypromellose capsugel white/brown g4ics000510 lactose monohydrate magnesium stearate - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidneys) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.